Top

Published in:

Open Access 01-08-2016 | Original Article

IMRT/VMAT for malignancies in the head-and-neck region

Outcome in patients aged 80+

Authors: Michelle L. Brown, MBBS, FRANZCR, MPH, Prof Christoph Glanzmann, Gerhard Huber, PD, Marius Bredell, BChD MBChB MChD, Tamara Rordorf, MD, Prof Gabriela Studer

Published in: Strahlentherapie und Onkologie | Issue 8/2016

Abstract

Objective

Elderly patients with malignant head-and-neck tumors (HNT) often pose a therapeutic challenge. They frequently have significant comorbidities which may influence their ability to tolerate tumor-specific therapies. Our aim was to investigate the outcome of patients aged 80+ years undergoing curative intent intensity- or volume-modulated radiation therapy (IMRT/VMAT).

Methods

We retrospectively reviewed our HNT patients aged 80+ treated with curative IMRT/VMAT from December 2003 to November 2015. Overall survival (OS), disease-free survival (DFS), local control (LC), and treatment tolerance were assessed. Outcome results were compared with that of a younger HNT patient cohort from our hospital.

Results

A total of 140 consecutive patients were included (65 postoperative, 75 definitive). Mean/median age at treatment start was 84.8/84.1 years (range 80–96 years). Mean/median follow-up time was 25/16 months (range 2–92 months). Of the 140 patients, 80 were alive with no evidence of disease when last seen, 28 had died due to the cancer, 12 remained alive with disease, the remaining 20 died intercurrently. Systemic concomitant therapy was administered in 7 %. Late grade 3–4 toxicity was observed in 2 %. All patients completed treatment. Hospitalization and feeding tube rates were 26 % and 11 %, respectively. The 2‑/3-year LC, DFS, and OS rates for the entire cohort were 81/80 %, 69/63 %, and 68/66 %, respectively. Squamous cell carcinoma (SCC) patients showed an inferior 3-year OS rate as compared to non-SCC patients (62 % vs 77 %, p = 0.0002), while LC and DFS did not differ. Patients undergoing postoperative radiation attained a higher OS compared to the definitively irradiated subgroup with 74 vs. 60 % at 3 years (p = 0.01); however, DFS rates were similar for both groups (68 vs. 61 %, p = 0.15). Corresponding rates for >1400 HNT patients <80 years treated during the same time interval were 81/80 %, 69/67 %, and 77/72 %, respectively.

Conclusions

Treatment tolerance in our patients aged 80+ was high. These results suggest that elderly HNT patients should not be denied potentially curative treatment strategies.

Pignon JP, Maître A le, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14CrossRefPubMed

National Cancer Institute Surveillance, Epidemiology, and End Results Program. http://www.seer.cancer.gov. Accessed 30. April 2015

Swiss Federal Statistical Office (2010) The population of Switzerland 2009. Federal Department of Home Affairs, Neuchâtel

Parker SL, Tong T, Bolden S et al (1997) Cancer statistics, 1997. CA Cancer J Clin 47(1):5–27CrossRefPubMed

Siddiqui F, Gwede CK (2012) Head and neck cancer in the elderly population. Semin Radiat Oncol 22(4):321–333CrossRefPubMed

Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136CrossRefPubMedPubMedCentral

Studer G, Linsenmeier C, Riesterer O et al (2013) Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol 8:259CrossRefPubMedPubMedCentral

Lusinchi A, Bourhis J, Wibault P et al (1990) Radiation therapy for head and neck cancers in the elderly. Int J Radiat Oncol Biol Phys 18(4):819–823CrossRefPubMed

Huguenin P, Sauer M, Glanzmann C et al (1996) Radiotherapy for carcinomas of the head and neck in elderly patients. Strahlenther Onkol 172(9):485–488PubMed

10.

Pignon T, Horiot J‑C, Van den Bogaert W et al (1996) No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer 32A(12):2075–2081CrossRefPubMed

11.

Zachariah B, Balducci L, Venkattaramanabalaji GV et al (1997) Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 39(5):1125–1129CrossRefPubMed

12.

Mitsuhashi N, Hayakawa K, Yamakawa M et al (1999) Cancer in patients aged 90 years or older: radiation therapy. Radiology 211(3):829–833CrossRefPubMed

13.

Allal AS, Maire D, Becker M et al (2000) Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer 88(3):648–652CrossRefPubMed

14.

Schofield CP, Sykes AJ, Slevin NJ et al (2003) Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 69(1):37–42CrossRefPubMed

15.

Huang SH, O’Sullivan B, Waldron J et al (2011) Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys 79(1):46–51CrossRefPubMed

16.

Kodaira T, Fuwa N, Furutani K et al (2005) Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 35(4):173–176CrossRefPubMed

17.

Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589CrossRefPubMedPubMedCentral

18.

Koussis H, Scola A, Bergamo F et al (2008) Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. Anticancer Res 28(2B):1383–1388PubMed

19.

Tsukuda M, Ishitoya J, Mikami Y et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S‑1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64(5):945–952CrossRefPubMedPubMedCentral

20.

Boscolo-Rizzo P, Gava A, Marchiori C et al (2011) Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 268(9):1349–1355CrossRefPubMed

21.

Nguyen NP, Vock J, Chi A et al (2012) Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol 188(8):677–683CrossRefPubMed

22.

Merlano MC, Monteverde M, Colantonio I et al (2012) Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol 48(10):1051–1057CrossRefPubMed

23.

Michal SA, Adelstein D, Rybicki LA et al (2012) Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck 34(8):1147–1152CrossRefPubMed

24.

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28CrossRefPubMed

25.

Alongi F, Bignardi M, Garassino I et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188(1):49–55CrossRefPubMed

26.

Brugel L, Laurent M, Caillet P et al (2014) Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a multicentre randomised controlled trial (EGeSOR). BMC Cancer 14:427CrossRefPubMedPubMedCentral

27.

Kunkler IH, Audisio R, Belkacemi Y et al (2014) Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol 25(11):2134–2146CrossRefPubMed

Title: IMRT/VMAT for malignancies in the head-and-neck region
Outcome in patients aged 80+
Authors: Michelle L. Brown, MBBS, FRANZCR, MPH
Prof Christoph Glanzmann
Gerhard Huber, PD
Marius Bredell, BChD MBChB MChD
Tamara Rordorf, MD
Prof Gabriela Studer
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 8/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0986-8

At a glance: The STEP trials

Springer Medicine

IMRT/VMAT for malignancies in the head-and-neck region

Outcome in patients aged 80+

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

Modulation of radiation-induced oral mucositis by thalidomide

Restaging-PET-CT nach Radiochemotherapie kann Patienten mit fortgeschrittenen HNO-Karzinomen die elektive Neck-Dissektion ersparen, sofern sie eine komplette Remission zeigen

The field size matters: low dose external beam radiotherapy for thumb carpometacarpal osteoarthritis

Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers

Open source deformable image registration system for treatment planning and recurrence CT scans

Der Stellenwert der Operation bei der Behandlung des resektablen nicht-kleinzelligen Lungenkarzinoms im Stadium III